You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuinacrine
Accession NumberDB01103  (APRD00317)
TypeSmall Molecule
GroupsApproved
DescriptionAn acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. [PubChem]
Structure
Thumb
Synonyms
2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine
3-chloro-7-Methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine
6-chloro-9-((4-(Diethylamino)-1-methylbutyl)amino)-2-methoxyacridine
Mepacrine
N(4)-(6-chloro-2-Methoxy-9-acridinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
Quinacrine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AtabrineNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Quinacrine Dihydrochloride
Thumb
  • InChI Key: UDKVBVICMUEIKS-UHFFFAOYNA-N
  • Monoisotopic Mass: 471.161095782
  • Average Mass: 472.879
DBSALT000420
Categories
UNIIH0C805XYDE
CAS number83-89-6
WeightAverage: 399.957
Monoisotopic: 399.207740304
Chemical FormulaC23H30ClN3O
InChI KeyInChIKey=GPKJTRJOBQGKQK-UHFFFAOYSA-N
InChI
InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)
IUPAC Name
6-chloro-N-[5-(diethylamino)pentan-2-yl]-2-methoxyacridin-9-amine
SMILES
CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=C1C=CC(Cl)=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acridines. These are organic compounds containing the acridine moiety, a linear tricyclic heterocycle which consists of two benzene rings joined by a pyridine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassBenzoquinolines
Direct ParentAcridines
Alternative Parents
Substituents
  • Acridine
  • Chloroquinoline
  • Hydroxyquinoline
  • Aminoquinoline
  • Anisole
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Aminopyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Secondary amine
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions.
PharmacodynamicsQuinacrine has been used as an antimalarial drug and as an antibiotic. It is used to treat giardiasis, a protozoal infection of the intestinal tract, and certain types of lupus erythematosus, an inflammatory disease that affects the joints, tendons, and other connective tissues and organs. Quinacrine may be injected into the space surrounding the lungs to prevent reoccurrence of pneumothorax. The exact way in which quinacrine works is unknown. It appears to interfere with the parasite's metabolism.
Mechanism of actionThe exact mechanism of antiparasitic action is unknown; however, quinacrine binds to deoxyribonucleic acid (DNA) in vitro by intercalation between adjacent base pairs, inhibiting transcription and translation to ribonucleic acid (RNA). Quinacrine does not appear to localize to the nucleus of Giaridia trophozoites, suggesting that DNA binding may not be the primary mechanism of its antimicrobial action. Fluorescence studies using Giardia suggest that the outer membranes may be involved. Quinacrine inhibits succinate oxidation and interferes with electron transport. In addition, by binding to nucleoproteins, quinacrine suppress the lupus erythematous cell factor and acts as a strong inhibitor of cholinesterase.
Related Articles
AbsorptionAbsorbed rapidly from the gastrointestinal tract following oral administration.
Volume of distributionNot Available
Protein binding80-90%
MetabolismNot Available
Route of eliminationNot Available
Half life5 to 14 days
ClearanceNot Available
ToxicityOral, rat: LD50 = 900 mg/kg; Oral, mouse: LD50 = 1000 mg/kg. Symptoms of overdose include seizures, hypotension, cardiac arrhythmias, and cardiovascular collapse.
Affected organisms
  • Parasitic protozoa and helminths
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.9253
Caco-2 permeable+0.596
P-glycoprotein substrateSubstrate0.8401
P-glycoprotein inhibitor IInhibitor0.7537
P-glycoprotein inhibitor IIInhibitor0.8526
Renal organic cation transporterInhibitor0.6497
CYP450 2C9 substrateNon-substrate0.8442
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.701
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9185
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9063
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5494
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.8806
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8888 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.585
hERG inhibition (predictor II)Inhibitor0.8622
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Quinacrine hcl powder8.11USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248-250 °CNot Available
water solubilitySlightNot Available
logP5.5Not Available
pKa10.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00239 mg/mLALOGPS
logP6.13ALOGPS
logP5.15ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)10.33ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.39 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity118.96 m3·mol-1ChemAxon
Polarizability46.32 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US2113357
General References
  1. Canete R, Escobedo AA, Gonzalez ME, Almirall P: Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children. World J Gastroenterol. 2006 Oct 21;12(39):6366-70. [PubMed:17072963 ]
  2. Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y: The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol. 2006 Apr;63(4):299-303. [PubMed:16623930 ]
  3. Zipper J, Cole LP, Goldsmith A, Wheeler R, Rivera M: Quinacrine hydrochloride pellets: preliminary data on a nonsurgical method of female sterilization. Int J Gynaecol Obstet. 1980;18(4):275-9. [PubMed:6109672 ]
  4. Bhatt RV: Camp laparoscopic sterilization deaths in Gujarat State, India, 1978-1980. Asia Oceania J Obstet Gynaecol. 1991 Dec;17(4):297-301. [PubMed:1839351 ]
  5. Peterson HB, Lubell I, DeStefano F, Ory HW: The safety and efficacy of tubal sterilization: an international overview. Int J Gynaecol Obstet. 1983 Apr;21(2):139-44. [PubMed:6136433 ]
External Links
ATC CodesP01AX05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Quinacrine.
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Quinacrine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Quinacrine.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Quinacrine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Quinacrine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Quinacrine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Quinacrine.
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Quinacrine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Quinacrine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Quinacrine.
AmiodaroneThe metabolism of Quinacrine can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Quinacrine.
AmodiaquineThe serum concentration of Quinacrine can be decreased when it is combined with Amodiaquine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Quinacrine.
AprepitantThe serum concentration of Quinacrine can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Quinacrine.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Quinacrine.
AtazanavirThe metabolism of Quinacrine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Quinacrine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Quinacrine.
AtomoxetineThe metabolism of Quinacrine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Quinacrine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Quinacrine.
BevacizumabBevacizumab may increase the cardiotoxic activities of Quinacrine.
BexaroteneThe serum concentration of Quinacrine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Quinacrine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Quinacrine.
BortezomibThe metabolism of Quinacrine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Quinacrine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Quinacrine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Quinacrine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Quinacrine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Quinacrine.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Quinacrine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Quinacrine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Quinacrine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Quinacrine.
CarbamazepineThe metabolism of Quinacrine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Quinacrine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Quinacrine.
CeritinibThe serum concentration of Quinacrine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Quinacrine.
ChloroquineThe serum concentration of Quinacrine can be decreased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Quinacrine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Quinacrine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Quinacrine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Quinacrine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Quinacrine.
ClarithromycinThe metabolism of Quinacrine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Quinacrine.
ClemastineThe metabolism of Quinacrine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Quinacrine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Quinacrine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Quinacrine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Quinacrine.
ClotrimazoleThe metabolism of Quinacrine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Quinacrine.
CobicistatThe metabolism of Quinacrine can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Quinacrine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Quinacrine.
ConivaptanThe serum concentration of Quinacrine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Quinacrine.
CrizotinibThe metabolism of Quinacrine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Quinacrine.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Quinacrine.
CyclosporineThe metabolism of Quinacrine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Quinacrine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quinacrine.
DabrafenibThe serum concentration of Quinacrine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Quinacrine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Quinacrine.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Quinacrine.
DapsoneThe risk or severity of adverse effects can be increased when Quinacrine is combined with Dapsone.
DarunavirThe metabolism of Quinacrine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Quinacrine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Quinacrine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Quinacrine.
DeferasiroxThe serum concentration of Quinacrine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Quinacrine can be decreased when combined with Delavirdine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Quinacrine.
DexamethasoneThe serum concentration of Quinacrine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Quinacrine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Quinacrine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Quinacrine.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Quinacrine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Quinacrine.
DigoxinDigoxin may decrease the cardiotoxic activities of Quinacrine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Quinacrine.
DihydroergotamineThe metabolism of Quinacrine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Quinacrine.
DiltiazemThe metabolism of Quinacrine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Quinacrine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Quinacrine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Quinacrine.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Quinacrine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Quinacrine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Quinacrine.
DoxycyclineThe metabolism of Quinacrine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Quinacrine can be decreased when combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Quinacrine.
EfavirenzThe serum concentration of Quinacrine can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Quinacrine.
EnzalutamideThe serum concentration of Quinacrine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Quinacrine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Quinacrine.
ErythromycinThe metabolism of Quinacrine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Quinacrine.
Eslicarbazepine acetateThe serum concentration of Quinacrine can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Quinacrine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Quinacrine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Quinacrine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Quinacrine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Quinacrine.
EtravirineThe serum concentration of Quinacrine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Quinacrine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Quinacrine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Quinacrine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Quinacrine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Quinacrine.
FluconazoleThe metabolism of Quinacrine can be decreased when combined with Fluconazole.
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Quinacrine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Quinacrine.
FluvoxamineThe metabolism of Quinacrine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Quinacrine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Quinacrine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Quinacrine can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Quinacrine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Quinacrine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Quinacrine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Quinacrine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Quinacrine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Quinacrine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Quinacrine.
HydroxychloroquineThe serum concentration of Quinacrine can be decreased when it is combined with Hydroxychloroquine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Quinacrine.
IdelalisibThe serum concentration of Quinacrine can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Quinacrine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Quinacrine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Quinacrine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Quinacrine.
IndinavirThe metabolism of Quinacrine can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Quinacrine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Quinacrine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Quinacrine.
IsavuconazoniumThe metabolism of Quinacrine can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Quinacrine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Quinacrine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Quinacrine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Quinacrine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Quinacrine.
KetoconazoleThe metabolism of Quinacrine can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Quinacrine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Quinacrine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Quinacrine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Quinacrine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Quinacrine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Quinacrine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Quinacrine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Quinacrine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Quinacrine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Quinacrine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Quinacrine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Quinacrine.
LopinavirThe metabolism of Quinacrine can be decreased when combined with Lopinavir.
LosartanThe serum concentration of Losartan can be increased when it is combined with Quinacrine.
LovastatinThe metabolism of Quinacrine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Quinacrine can be increased when it is combined with Luliconazole.
LumefantrineThe risk or severity of adverse effects can be increased when Quinacrine is combined with Lumefantrine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Quinacrine.
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Quinacrine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Quinacrine.
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Quinacrine.
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Quinacrine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Quinacrine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Quinacrine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Quinacrine.
MifepristoneThe metabolism of Quinacrine can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Quinacrine.
MitotaneThe serum concentration of Quinacrine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Quinacrine.
ModafinilThe serum concentration of Quinacrine can be decreased when it is combined with Modafinil.
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Quinacrine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Quinacrine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinacrine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Quinacrine.
NafcillinThe serum concentration of Quinacrine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Quinacrine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Quinacrine.
NefazodoneThe metabolism of Quinacrine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Quinacrine can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Quinacrine.
NetupitantThe serum concentration of Quinacrine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Quinacrine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Quinacrine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Quinacrine.
NilotinibThe metabolism of Quinacrine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Quinacrine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Quinacrine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Quinacrine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Quinacrine.
OlaparibThe metabolism of Quinacrine can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Quinacrine.
OsimertinibThe serum concentration of Quinacrine can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Quinacrine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Quinacrine.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quinacrine.
PalbociclibThe serum concentration of Quinacrine can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Quinacrine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Quinacrine.
PentobarbitalThe metabolism of Quinacrine can be increased when combined with Pentobarbital.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Quinacrine.
PhenobarbitalThe metabolism of Quinacrine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Quinacrine.
PhenytoinThe metabolism of Quinacrine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Quinacrine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Quinacrine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Quinacrine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Quinacrine.
PosaconazoleThe metabolism of Quinacrine can be decreased when combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Quinacrine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Quinacrine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Quinacrine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Quinacrine.
PrimaquineThe serum concentration of Quinacrine can be decreased when it is combined with Primaquine.
PrimidoneThe metabolism of Quinacrine can be increased when combined with Primidone.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Quinacrine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Quinacrine.
PromazineThe serum concentration of Promazine can be increased when it is combined with Quinacrine.
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Quinacrine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Quinacrine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Quinacrine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Quinacrine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Quinacrine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Quinacrine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Quinacrine.
RanolazineThe metabolism of Quinacrine can be decreased when combined with Ranolazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Quinacrine.
RifabutinThe metabolism of Quinacrine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Quinacrine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Quinacrine.
RifapentineThe metabolism of Quinacrine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Quinacrine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Quinacrine.
RitonavirThe metabolism of Quinacrine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Quinacrine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Quinacrine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Quinacrine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Quinacrine.
SaquinavirThe metabolism of Quinacrine can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Quinacrine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Quinacrine.
SildenafilThe metabolism of Quinacrine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Quinacrine.
SiltuximabThe serum concentration of Quinacrine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Quinacrine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Quinacrine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Quinacrine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Quinacrine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Quinacrine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Quinacrine.
St. John's WortThe serum concentration of Quinacrine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Quinacrine can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Quinacrine can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Quinacrine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Quinacrine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Quinacrine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Quinacrine.
TelaprevirThe metabolism of Quinacrine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Quinacrine.
TelithromycinThe metabolism of Quinacrine can be decreased when combined with Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Quinacrine.
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Quinacrine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Quinacrine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Quinacrine.
TiclopidineThe metabolism of Quinacrine can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Quinacrine.
TocilizumabThe serum concentration of Quinacrine can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Quinacrine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Quinacrine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Quinacrine.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Quinacrine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Quinacrine.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinacrine.
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Quinacrine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Quinacrine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Quinacrine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Quinacrine.
VenlafaxineThe metabolism of Quinacrine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Quinacrine.
VerapamilThe metabolism of Quinacrine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Quinacrine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Quinacrine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Quinacrine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Quinacrine.
VoriconazoleThe metabolism of Quinacrine can be decreased when combined with Voriconazole.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Quinacrine.
ZiprasidoneThe metabolism of Quinacrine can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hossain M, Giri P, Kumar GS: DNA intercalation by quinacrine and methylene blue: a comparative binding and thermodynamic characterization study. DNA Cell Biol. 2008 Feb;27(2):81-90. [PubMed:17924822 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phospholipase a2 activity
Specific Function:
Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells. Has a role in cardiolipin (CL) deacylation. Requir...
Gene Name:
PLA2G6
Uniprot ID:
O60733
Molecular Weight:
89902.295 Da
References
  1. Nuttle LC, Ligon AL, Farrell KR, Hester RL: Inhibition of phospholipase A2 attenuates functional hyperemia in the hamster cremaster muscle. Am J Physiol. 1999 Apr;276(4 Pt 2):H1289-94. [PubMed:10199854 ]
  2. Sastry BV, Hemontolor ME, Vidaver PS, Sastry WS, Janson VE: Influence of halothane on phospholipase A2 and enzymatic methylations in the rat retinal membranes. J Ocul Pharmacol Ther. 1999 Apr;15(2):165-78. [PubMed:10229494 ]
  3. Lohmann CH, Sagun R Jr, Sylvia VL, Cochran DL, Dean DD, Boyan BD, Schwartz Z: Surface roughness modulates the response of MG63 osteoblast-like cells to 1,25-(OH)(2)D(3) through regulation of phospholipase A(2) activity and activation of protein kinase A. J Biomed Mater Res. 1999 Nov;47(2):139-51. [PubMed:10449625 ]
  4. Schwartz Z, Sylvia VL, Del Toro F, Hardin RR, Dean DD, Boyan BD: 24R,25-(OH)(2)D(3) mediates its membrane receptor-dependent effects on protein kinase C and alkaline phosphatase via phospholipase A(2) and cyclooxygenase-1 but not cyclooxygenase-2 in growth plate chondrocytes. J Cell Physiol. 2000 Mar;182(3):390-401. [PubMed:10653606 ]
  5. Sylvia VL, Del Toro F, Dean DD, Hardin RR, Schwartz Z, Boyan BD: Effects of 1alpha,25-(OH)(2)D(3) on rat growth zone chondrocytes are mediated via cyclooxygenase-1 and phospholipase A(2). J Cell Biochem Suppl. 2001;Suppl 36:32-45. [PubMed:11455568 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Molecular Weight:
85238.2 Da
References
  1. Hellstrand M, Eriksson E, Nilsson CL: Dopamine D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent. Biochem Pharmacol. 2002 Jun 15;63(12):2151-8. [PubMed:12110374 ]
  2. Ong WY, Lu XR, Ong BK, Horrocks LA, Farooqui AA, Lim SK: Quinacrine abolishes increases in cytoplasmic phospholipase A2 mRNA levels in the rat hippocampus after kainate-induced neuronal injury. Exp Brain Res. 2003 Feb;148(4):521-4. Epub 2002 Dec 11. [PubMed:12582837 ]
  3. Kim BC, Kim JH: Exogenous C2-ceramide activates c-fos serum response element via Rac-dependent signalling pathway. Biochem J. 1998 Mar 1;330 ( Pt 2):1009-14. [PubMed:9480923 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Signal transducer activity
Specific Function:
Involved in an inositol phospholipid-based intracellular signaling cascade. Shows no PLC activity to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol. Component in the phospho-dependent endocytosis process of GABA A receptor (By similarity). Regulates the turnover of receptors and thus contributes to the maintenance of GABA-mediated synaptic inhibition. Its aberrant expression cou...
Gene Name:
PLCL1
Uniprot ID:
Q15111
Molecular Weight:
122726.98 Da
References
  1. Biondi C, Pavan B, Ferretti ME, Corradini FG, Neri LM, Vesce F: Formyl-methionyl-leucyl-phenylalanine induces prostaglandin E2 release from human amnion-derived WISH cells by phospholipase C-mediated [Ca+]i rise. Biol Reprod. 2001 Mar;64(3):865-70. [PubMed:11207202 ]
  2. Takuwa N, Kumada M, Yamashita K, Takuwa Y: Mechanisms of bombesin-induced arachidonate mobilization in Swiss 3T3 fibroblasts. J Biol Chem. 1991 Aug 5;266(22):14237-43. [PubMed:1860838 ]
  3. Otamiri T: Phospholipase C-mediated intestinal mucosal damage is ameliorated by quinacrine. Food Chem Toxicol. 1989 Jun;27(6):399-402. [PubMed:2551803 ]
  4. Noveral JP, Grunstein MM: Tachykinin regulation of airway smooth muscle cell proliferation. Am J Physiol. 1995 Sep;269(3 Pt 1):L339-43. [PubMed:7573467 ]
  5. Bjoro T, Englund K, Torjesen PA, Haug E: Inhibitors of the arachidonic acid metabolism attenuate the thyroliberin (TRH) stimulated prolactin production without modifying the production of inositolphosphates in GH4C1 pituitary cells. Scand J Clin Lab Invest. 1993 Apr;53(2):111-6. [PubMed:8469910 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Histamine n-methyltransferase activity
Specific Function:
Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine.
Gene Name:
HNMT
Uniprot ID:
P50135
Molecular Weight:
33294.765 Da
References
  1. Grassmann S, Apelt J, Sippl W, Ligneau X, Pertz HH, Zhao YH, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Stark H: Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities. Bioorg Med Chem. 2003 May 15;11(10):2163-74. [PubMed:12713826 ]
  2. Hui JY, Taylor SL: Inhibition of in vivo histamine metabolism in rats by foodborne and pharmacologic inhibitors of diamine oxidase, histamine N-methyltransferase, and monoamine oxidase. Toxicol Appl Pharmacol. 1985 Nov;81(2):241-9. [PubMed:3933141 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Sweet DH, Pritchard JB: rOCT2 is a basolateral potential-driven carrier, not an organic cation/proton exchanger. Am J Physiol. 1999 Dec;277(6 Pt 2):F890-8. [PubMed:10600936 ]
  2. Dohgu S, Yamauchi A, Takata F, Sawada Y, Higuchi S, Naito M, Tsuruo T, Shirabe S, Niwa M, Katamine S, Kataoka Y: Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier. Cell Mol Neurobiol. 2004 Apr;24(2):205-17. [PubMed:15176436 ]
  3. Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR: Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun. 1988 Jun 30;153(3):959-66. [PubMed:2898941 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78. [PubMed:8862725 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23